Staging systems for papillary thyroid carcinoma: a review and comparison
- PMID: 17435543
- PMCID: PMC1877011
- DOI: 10.1097/01.sla.0000250445.92336.2a
Staging systems for papillary thyroid carcinoma: a review and comparison
Abstract
Objective: To find out the most predictive staging system for papillary thyroid carcinoma (PTC) currently available in the literature.
Background: Various staging systems or risk group stratifications have been used extensively in the clinical management of patients with PTC, but the most predictive system for cancer-specific survival (CSS) based on distinct histologic types remains unclear.
Methods: Through a comprehensive MEDLINE search from 1965 to 2005, a total of 17 staging systems were found in the literature and 14 systems were applied to the 589 PTC patients managed at our institution from 1961 to 2001. CSS were calculated by Kaplan-Meier method and were compared by log-rank test. Using Cox proportional hazards analysis, the relative importance of each staging system in determining CSS was calculated by the proportion of variation (PVE).
Results: All 14 staging systems significantly predicted CSS (P < 0.001). The 3 highest ranked staging systems by PVE were the Metastases, Age, Completeness of Resection, Invasion, Size (MACIS) (18.7) followed by the new AJCC/UICC 6th edition tumor, node, metastases (TNM) (17.9), and the European Organization for Research and Treatment of Cancer (EORTC) (16.6).
Conclusions: All of the currently available staging systems predicted CSS well in patients with PTC regardless of which histologic type from which they were derived. When predictability was measured by PVE, the MACIS system was the most predictive staging system and so should be the staging system of choice for PTC in the future.
Similar articles
-
Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre.Endocr Relat Cancer. 2007 Mar;14(1):29-42. doi: 10.1677/erc.1.01284. Endocr Relat Cancer. 2007. PMID: 17395973 Review.
-
Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers.Ann Surg. 2007 Jul;246(1):114-21. doi: 10.1097/01.sla.0000262785.46403.9b. Ann Surg. 2007. PMID: 17592299 Free PMC article.
-
Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability.Ann Surg Oncol. 2007 May;14(5):1551-9. doi: 10.1245/s10434-006-9242-2. Epub 2007 Feb 21. Ann Surg Oncol. 2007. PMID: 17318278
-
Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution.Ann Surg. 2003 Feb;237(2):227-34. doi: 10.1097/01.SLA.0000048449.69472.81. Ann Surg. 2003. PMID: 12560781 Free PMC article.
-
A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example.Cancer. 1997 Jun 15;79(12):2414-23. Cancer. 1997. PMID: 9191532 Review.
Cited by
-
Postablation stimulated thyroglobulin level is an important predictor of biochemical complete remission after reoperative cervical neck dissection in persistent/recurrent papillary thyroid carcinoma.Ann Surg Oncol. 2013 Feb;20(2):653-9. doi: 10.1245/s10434-012-2624-8. Epub 2012 Sep 7. Ann Surg Oncol. 2013. PMID: 22956067 Free PMC article.
-
A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry.Surgery. 2012 Aug;152(2):145-51. doi: 10.1016/j.surg.2012.02.015. Epub 2012 Apr 11. Surgery. 2012. PMID: 22503316 Free PMC article.
-
Dynamic Risk Stratification for Predicting Treatment Response in Differentiated Thyroid Cancer.J Clin Med. 2020 Aug 21;9(9):2708. doi: 10.3390/jcm9092708. J Clin Med. 2020. PMID: 32825789 Free PMC article.
-
Current concepts and future directions in differentiated thyroid cancer.Clin Biochem Rev. 2010 Feb;31(1):9-19. Clin Biochem Rev. 2010. PMID: 20179793 Free PMC article.
-
Prediction model of cervical lymph node metastasis based on clinicopathological characteristics of papillary thyroid carcinoma: a dual-center retrospective study.Front Endocrinol (Lausanne). 2023 Sep 11;14:1233929. doi: 10.3389/fendo.2023.1233929. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37766691 Free PMC article.
References
-
- Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501–511. - PubMed
-
- Lang BH, Lo CY, Chan WF, et al. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. In press. - PubMed
-
- Cancer incidence and mortality in Hong Kong from 1983 to 2002. Hong Kong Cancer Registry, Hong Kong. Available at: http://www3.ha.org.hk/cancereg/stat.asp. Accessed April 25, 2006.
-
- Haselkorn T, Bernstein L, Preston-Martin S, et al. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972–1995. Cancer Causes Control. 2000;11:163–170. - PubMed
-
- Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol. 2004;11:1093–1097. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical